VDV Pharma
Turnover is estimated at about €970,000, probably between €760,000 and €1.3m.
Balance sheet
balance sheet total €1.5m on 30-06-2025in euro
in euro
Position in the sector
13.3%
Higher than 25% of the 6,427 companies filing full accounts in retail trade (NACE 47) in 2024.
0.47
Higher than 7% of the 6,379 companies filing full accounts in retail trade (NACE 47) in 2024.
4.4%
Higher than 54% of the 6,401 companies filing full accounts in retail trade (NACE 47) in 2024.
Staff
€63,619
Staff costs divided by the average number of full-time equivalents.
+1 employee
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 202111 months |
|---|---|---|---|---|---|---|
| 182,818 | 231,503 | 197,001 | 195,534 | 51,327 | ||
| 139,698 | 175,912 | 149,584 | 155,196 | 41,176 | ||
| 41,804 | 6,593 | 1.1m | 2,123 | 327,382 | ||
| -77,882 | 76,612 | -40,931 | 90,664 | - | ||
| -392,026 | -440,728 | -324,562 | 154,884 | 36,058 | ||
| 13.3% | 8.3% | 15.6% | 29.4% | 9.9% | ||
| 0.47 | 0.49 | 0.50 | 2.19 | 1.44 | ||
| 0.31 | 0.36 | 0.36 | 1.63 | 0.80 | ||
| 6.54 | 11.04 | 5.42 | 2.40 | 9.09 | ||
| 33.0% | 78.9% | 34.0% | 74.5% | 40.3% | ||
| 4.4% | 6.6% | 5.3% | 21.9% | 4.0% | ||
| 7.43 | 8.91 | 7.28 | 29.79 | - |
EBIT margin not included in this filing.
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 202111 months |
|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||
20/58 |
1.5m | 1.6m | 1.6m | 558,270 | 422,453 | |
20 |
8 | 210 | 412 | 614 | 816 | |
21/28 |
1.2m | 1.2m | 1.3m | 272,505 | 303,259 | |
21 |
303,750 | 353,250 | 402,750 | 247,500 | 277,500 | |
22/27 |
360,833 | 342,653 | 357,153 | 24,855 | 25,609 | |
22 |
313,820 | 318,560 | 330,845 | - | - | |
23 |
17,845 | 20,904 | 20,660 | 22,472 | 25,137 | |
24 |
3,027 | 3,189 | 5,648 | 2,383 | 472 | |
25 |
26,140 | - | - | - | - | |
28 |
508,336 | 508,336 | 506,840 | 150 | 150 | |
29/58 |
345,230 | 421,098 | 328,810 | 285,151 | 118,378 | |
3 |
118,891 | 106,770 | 90,386 | 73,232 | 52,631 | |
30/36 |
118,891 | 106,770 | 90,386 | 73,232 | 52,631 | |
40/41 |
91,277 | 126,295 | 158,574 | 106,300 | 51,133 | |
40 |
79,777 | 88,679 | 111,636 | 73,896 | 51,101 | |
41 |
11,500 | 37,616 | 46,938 | 32,403 | 32 | |
50/53 |
68,884 | 45,000 | 15,000 | - | - | |
54/58 |
62,510 | 140,392 | 63,780 | 104,711 | 14,047 | |
490/1 |
3,669 | 2,641 | 1,070 | 908 | 567 | |
| Balance sheet: equity and liabilities | ||||||
10/49 |
1.5m | 1.6m | 1.6m | 558,270 | 422,453 | |
10/15 |
201,427 | 135,056 | 248,442 | 163,976 | 41,859 | |
10/11 |
25,000 | 25,000 | 25,000 | 25,000 | 25,000 | |
14 |
176,427 | 110,056 | 223,442 | 138,976 | 16,859 | |
17/49 |
1.3m | 1.5m | 1.3m | 394,294 | 380,594 | |
17 |
579,474 | 627,479 | 693,047 | 264,027 | 298,274 | |
170/4 |
579,474 | 627,479 | 693,047 | 264,027 | 298,274 | |
42/48 |
737,257 | 861,826 | 653,371 | 130,267 | 82,320 | |
42 |
73,646 | 67,076 | 63,985 | 34,247 | 33,744 | |
43 |
30,000 | 30,000 | 30,000 | 20,000 | - | |
430/8 |
30,000 | 30,000 | 30,000 | 20,000 | - | |
44 |
50,491 | 50,115 | 281,188 | 43,262 | 35,350 | |
440/4 |
50,491 | 50,115 | 281,188 | 43,262 | 35,350 | |
45 |
19,349 | 15,797 | 15,346 | 32,759 | 10,535 | |
450/3 |
327 | 4,110 | 3,901 | 19,971 | 5,645 | |
454/9 |
19,022 | 11,688 | 11,446 | 12,787 | 4,889 | |
47/48 |
563,771 | 698,838 | 262,853 | 0 | 2,692 | |
492/3 |
0 | 1,187 | 1,105 | - | - | |
| Income statement | ||||||
9900 |
281,698 | 301,615 | 265,189 | 272,343 | 108,592 | |
62 |
95,429 | 64,773 | 66,643 | 76,809 | 56,915 | |
630 |
73,327 | 69,298 | 65,119 | 33,079 | 24,317 | |
640/8 |
3,451 | 5,339 | 1,545 | 0 | 350 | |
9901 |
109,491 | 162,205 | 131,883 | 162,455 | 27,010 | |
75/76B |
0 | 1,957 | 2,419 | 932 | - | |
75 |
0 | 1,957 | 2,419 | 932 | - | |
65/66B |
24,592 | 25,990 | 27,052 | 6,565 | 6,291 | |
65 |
24,592 | 25,990 | 27,052 | 6,565 | 6,291 | |
9903 |
84,899 | 138,172 | 107,249 | 156,822 | 20,719 | |
67/77 |
18,528 | 31,557 | 22,784 | 34,705 | 3,860 | |
9904 |
66,371 | 106,614 | 84,465 | 122,117 | 16,859 | |
9905 |
66,371 | 106,614 | 84,465 | 122,117 | 16,859 | |
| Appropriation of the result | ||||||
9906 |
176,427 | 330,056 | 223,442 | 138,976 | 16,859 | |
14P |
110,056 | 223,442 | 138,976 | 16,859 | - | |
694/7 |
0 | 220,000 | - | - | - | |
694 |
0 | 220,000 | - | - | - | |
| Social balance sheet | ||||||
9087 |
1.5 | 0.9 | 0.9 | 2 | 0.9 | |
Hours worked1013 |
2,518 | 1,471 | 1,500 | 2,024 | 1,734 | |
| Document | ||||||
The full notes are in the filed accounts (PDF).
Source: Annual accounts 2025 (PDF), filed on 17-11-2025.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 30-06-2025 | full format | 17-11-2025 | 2025-00567119 | |
| 30-06-2024 | full format | 07-01-2025 | 2025-00000428 | |
| 30-06-2023 | full format | 23-01-2024 | 2024-00004627 | |
| 30-06-2022 | micro format | 12-12-2022 | 2022-20535287 | |
| 30-06-2021 | micro format | 04-01-2022 | 2022-00100488 |
Social balance sheet
| Item | 30-06-2025 | 30-06-2024 | 30-06-2023 | 30-06-2022 |
|---|---|---|---|---|
| Employees at the balance-sheet date | 2 | 1 | 1 | 2 |
| full-time | 1 | 0 | 0 | 0 |
| part-time | 1 | 1 | 1 | 2 |
| in full-time equivalents | 1.8 | 0.8 | 0.8 | 1.1 |
| 1.5 | 0.9 | 0.9 | 1.1 | |
| On a permanent contract | 2 | 1 | 1 | 2 |
| Joined | 2 | - | 0 | - |
| Left | 1 | - | 1 | - |
Source: social balance sheet in the 2022 to 2025 annual accounts
Securities and guarantees
on own assets and for others| Item | 30-06-2025 | 30-06-2024 | 30-06-2023 | 30-06-2022 |
|---|---|---|---|---|
| Debts secured on the company's own assets | €653,120 | €694,556 | €757,031 | - |
| Mortgages, amount registered | €300,000 | €300,000 | €330,000 | - |
| Carrying value of the mortgaged assets | €313,821 | €328,976 | €333,103 | - |
| €603,932 | €603,932 | €603,932 | €357,000 |
Source: notes to the 2022 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)
Investments
fixed assets acquired| Item | 30-06-2025 | 30-06-2024 | 30-06-2023 | 30-06-2022 |
|---|---|---|---|---|
| Tangible fixed assets | €41,804 | €5,096 | €357,465 | €2,123 |
| Intangible fixed assets | - | - | €195,000 | - |
| Financial fixed assets | - | €1,497 | €506,690 | - |
| €73,327 | €69,298 | €65,119 | €33,079 |
Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)
Insights on VDV Pharma
The operating result for 2025 is 32% lower than in 2024 and the lowest since 2022.
Debt's share of the balance-sheet total falls from 91.7% to 86.7%. Equity is higher and debt is lower.
- 2022 Compared with 2021, the net result rose by 624%. The previous financial year ran 11 months, this one 12.